12 studies found for:    MPDL3280A
Show Display Options
Rank Status Study
1 Recruiting A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: MPDL3280A;   Drug: bevacizumab [Avastin];   Drug: sunitinib
2 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: MPDL3280A;   Drug: erlotinib [Tarceva[
3 Not yet recruiting A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: MPDL3280A;   Drug: Ipilimumab;   Drug: Interferon alfa-2b
4 Recruiting A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Condition: Carcinoma, Transitional Cell , Bladder Cancer, Bladder Tumors, Urinary Bladder Neoplasms
Intervention: Drug: MPDL3280A
5 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Condition: Malignant Melanoma
Interventions: Drug: MPDL3280A;   Drug: Vemurafenib (Zelboraf®)
6 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Interventions: Drug: MPDL3280A;   Drug: bevacizumab [Avastin];   Drug: FOLFOX;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pemetrexed;   Drug: nab-paclitaxel
7 Active, not recruiting A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "FIR"
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
8 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Interventions: Drug: Cobimetinib;   Drug: MPDL3280A
9 Recruiting A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
10 Recruiting A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: docetaxel
11 Recruiting A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Intervention: Drug: MPDL3280A
12 Recruiting A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK"
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: docetaxel

Indicates status has not been verified in more than two years